Dr. Anand Presented Interim Study Results of New Gene Therapy for X-linked Retinitis Pigmentosa at ASRS 2024 Annual Meeting
Texas Retina’s Rajiv Anand, MD, presented “Subretinal AGTC-501 Gene Therapy for XLRP: 12-Month Interim Safety & Efficacy Results of the Randomized Controlled Multicenter Phase II Skyline Trial” at the 2024 Annual Meeting
read more
Dr. Wang Presented Initial Study Results of New Non-infectious Uveitis Treatment at ASRS 2024 Annual Meeting
Texas Retina’s Robert C. Wang, MD, presented “Safety and Efficacy of Brepocitinib, a TYK2/JAK1 Inhibitor, in Active Non-Infectious Uveitis: 24-Week Results from a 52-Week Phase II Study (NEPTUNE)” at the 2024 Annual
read more
Dr. Abbey Presented Real-world Outcomes of Fluocinolone Acetonide Intravitreal Implant for Non-infectious Uveitis at ASRS 2024 Annual Meeting
Texas Retina’s Ashkan M. Abbey, MD, presented “36-month Optical Coherence Tomography Outcomes from CALM: A Registry Evaluating Treatment of Chronic Non-infectious Uveitis with the 0.18 mg Fluocinolone Acetonide Intravitreal Implant” at the
read more
Dr. Anand and Dr. Abbey Receive Senior Honor Awards from the American Society of Retina Specialists (ASRS)
In recognition of their time and contributions to the scientific programs of the organization’s annual meetings, Texas Retina’s Rajiv Anand, MD, and Ashkan M. Abbey, MD, recently earned the Senior Honor Award
read more
July is UV Safety Month — Debunking Seven Common Myths About Sunglasses
When most people think of UV protection, they think of their skin and sunscreen. Did you know that long-term exposure to bright sunlight may also increase your risk of eye disease? July
read more
Offices Closed on Thursday, July 4, 2024
All Texas Retina Associates offices will be closed on Thursday, July 4, 2024, in recognition of the Independence Day holiday and will reopen on Friday, July 5. We wish everyone a safe
read more